STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD
---------------------------------------------------------------------------------------------------------------------
IN THE MATTER OF RULE-MAKING : AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE : ORDER OF THE
CONTROLLED SUBSTANCES BOARD : CONTROLLED SUBSTANCES BOARD
---------------------------------------------------------------------------------------------------------------------
FINDINGS
1. On August 16, 2019, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Noroxymorphone into schedule II of the federal Controlled Substances Act. The scheduling action is effective August 16, 2019.
2. The Controlled Substances Board did not receive an objection to similarly listing Noroxymorphone as a schedule II under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing Noroxymorphone as a schedule II controlled substance. 3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.15 and omitting the notice of proposed rule making, listing Noroxymorphone as a schedule II controlled substance. ORDER
Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Noroxymorphone under chapter 961, Stats. by creating the following: CSB 2.69 Addition of Noroxymorphone to schedule II. Section 961.16 (2) (a)10m., Stats., is created to read:
961.16 (2) (a) 10m. Noroxymorphone.
This order shall take effect on November 11, 2019 to allow for publication in the Administrative Register. The order expires upon promulgation of a final rule.
Dated November 4, 2019 
Doug Englebert, Chair
Controlled Substances Board
